Alzheimer's Drugs Offer 'Trivial' Benefit While Increasing Brain Bleeding Risks
A comprehensive new scientific review has concluded that drugs marketed to slow Alzheimer's disease progression "make no meaningful difference to patients" while significantly increasing risks of dangerous brain swelling and bleeding. The analysis examined 17 separate studies involving over 20,000 patients, including trials of the licensed medications lecanemab and donanemab.
Minimal Clinical Impact Despite Statistical Significance
Researchers found that the effects of anti-amyloid drugs on cognitive function and dementia severity after 18 months were "trivial" and "far below the minimal effect that's needed to be noticeable at all for patients and caregivers." Professor Edo Richard, a neurology expert at Radboud University Medical Centre in the Netherlands who led the review, emphasized that while some trials showed statistically significant results, these did not translate into meaningful clinical improvements for patients.
"Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients," said Francesco Nonino, a neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna in Italy who contributed to the analysis. "There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect."
Significant Safety Concerns and Treatment Burden
The review identified substantial safety concerns, with the drugs increasing the risk of brain swelling and bleeding. While these side effects typically caused no immediate symptoms in most patients, their long-term impact remains unclear. Additionally, Professor Richard highlighted the considerable treatment burden, noting that patients would need to visit clinics every two to four weeks for intravenous infusions, undergo multiple scans and tests to confirm eligibility, and manage potential side effects.
"I would tell patients... I think you will probably not benefit from these drugs, and they're burdensome for you and your family," said Professor Richard, who runs a dementia clinic. "I just think it's extremely important that we're honest to our patients about what they can expect."
Charities Challenge Review Methodology
Alzheimer's charities have strongly challenged the review's conclusions, arguing that researchers have inappropriately "combined results for a majority of failed drug trials with a small number of more recent successful trials." Dr Richard Oakley, associate director of research and innovation at the Alzheimer's Society, emphasized that the UK medicines regulator had already agreed that lecanemab and donanemab bring "a modest but meaningful benefit for people with early-stage Alzheimer's."
Dr Susan Kohlhaas, executive director of research at Alzheimer's Research UK, noted that families regularly report that even a delay of several months in cognitive decline "could provide valuable, meaningful time" that "shouldn't be minimised." She criticized the review for attempting "to paint an entire class of drugs with the same brush" despite different anti-amyloid treatments acting in different ways.
Regulatory Context and Future Considerations
The review emerges as the National Institute for Health and Care Excellence (Nice) re-examines evidence on donanemab and lecanemab following successful appeals by manufacturers Eli Lilly and Eisai. Nice had previously declined to approve the treatments for NHS use, deeming their benefits "too small" to justify the substantial costs. Issues under reconsideration include quality of life impacts for caregivers and NHS England's cost estimates for infusion treatments.
Professor Jonathan Schott of the UK Dementia Research Institute at UCL noted methodological concerns, stating that "by combining studies of different drugs, many of which have long since been disbanded... it is almost inevitable that the conclusion will be that as a group they are clinically ineffective."
The analysis also highlighted that most studies reported results after only 18 months, which researchers described as a "relatively short" timeframe for a slowly progressive condition like Alzheimer's. In clinical practice, patients would likely use these medications for much longer periods, raising questions about longer-term efficacy and safety profiles.
